Oncology Research Institute (IPON), Federal University of the Triângulo Mineiro (UFTM). ; Discipline of Immunology, UFTM.
Clin Med Insights Oncol. 2013;7:75-81. doi: 10.4137/CMO.S11292. Epub 2013 Mar 6.
The aim of the study was to seek evidence for the production of IL-12 by CD4(+) T lymphocytes in in vitro and ex vivo trials. We performed in vitro trials with spleen cells from mice subjected to carcinogenesis, as well as ex vivo trials with cells obtained from the peripheral blood of healthy individuals and cancer patients. We were able to verify a significantly increased expression of IL-12 in CD4(+) T lymphocytes from mice and patients with tumors, compared to controls. Follow-up studies are needed to clarify whether this difference is related to being in a chronic disease state or whether it is an attempt by the immune system to produce an anti-tumor response, since T lymphocytes from healthy donors were not able to produce IL-12 when in contact with polyclonal stimuli. We concluded that, in cancer, T helper cells are capable of synthesizing IL-12, raising the question of whether we are faced with another profile, Th12.
本研究旨在寻找 CD4(+)T 淋巴细胞在体外和体内试验中产生 IL-12 的证据。我们进行了体外试验，使用了经历致癌作用的小鼠的脾细胞，还进行了体内试验，使用了来自健康个体和癌症患者外周血的细胞。我们能够证实，与对照组相比，来自患有肿瘤的小鼠和患者的 CD4(+)T 淋巴细胞中 IL-12 的表达明显增加。需要进一步的研究来阐明这种差异是否与处于慢性疾病状态有关，或者是否是免疫系统试图产生抗肿瘤反应，因为与多克隆刺激物接触时，来自健康供体的 T 淋巴细胞不能产生 IL-12。我们得出结论，在癌症中，辅助性 T 细胞能够合成 IL-12，这引发了一个问题，即我们是否面临另一种 Th12 细胞表型。
